A Phase I First-in-Human Study To Evaluate the Safety and Pharmacokinetic (PK) Properties of the Intravenously (IV) Administered OMN6
A Phase I First-in-Human Study To Evaluate the Safety and Pharmacokinetic (PK) Properties of the Intravenously (IV) Administered OMN6, a Novel Antimicrobial Peptide Targeting Acinetobacter Baumannii (A. Baumannii), In Adults Including Older Healthy Volunteers (HVS) Subjects Access Full Poster Background Acinetobacter baumannii (AB) is an opportunistic Gram-negative pathogen ranked 1st on the World Health Organization […]
Safety and Pharmacokinetic Results from the First-in-Human Study with Intravenously Administered OMN6 (A Poster)
Safety and Pharmacokinetic Results from the First-in-Human Study with Intravenously Administered OMN6, a Novel Antimicrobial Peptide for Acinetobacter baumannii (AB), Conducted in Healthy Volunteers Access Full Poster Background Serious Gram-negative bacterial infections, particularly those caused by Acinetobacter baumannii (AB), pose a significant global health threat due to increasing antibiotic resistance (1-2). OMN6 is a novel, biochemically-engineered antimicrobial […]
Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6
Designation underlines the need for novel, first-in-class antimicrobials for the treatment of infections with Gram-negative bacteria Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced that the Company has received fast-track designation for its novel anti-infective OMN6 from the U.S. Food and Drug Administration (FDA). Fast track expedited […]
Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6
JERUSALEM, Israel, November 20, 2023 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has approved a planned Phase II trial of the Company´s novel anti-infective OMN6. The multinational, multicenter trial will assess the safety and pharmacokinetics of OMN6 […]
OMN6 – Omnix Medical’s Lead Antimicrobial Peptide Receives Notice of Allowance from the Indian Patent Office
We are here to announce that the Indian Patent Office has issued a Notice of Allowance for Omnix Medical’s lead antimicrobial peptide for the treatment of infectious diseases. This pivotal achievement signifies that OMN6, developed with a commitment to revolutionize infectious disease treatment, has met the stringent criteria required for intellectual property protection. Importantly, the […]
Omnix Medical Announces Excellent Topline Data from the Phase I Clinical Trial of its Novel Anti-Infective OMN6
OMN6 demonstrates safety and tolerability at clinically significant dose levels JERUSALEM, Israel, May 8th, 2023 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced positive top-line results from the Phase I clinical trial of its lead compound OMN6, an anti-infective with a completely novel mechanism of action. […]
RECOGNITION AT EUROPEAN INNOVATION COUNCIL’S INVESTOR DAY
We are delighted to announce that Dr. Niv Bachnoff, our Chief Scientific Officer, has won the First Prize for Best Presentation in the Biotech & Pharmaceuticals category at the European Innovation Council’s Investor Day on Healthcare, which took place in Lisbon in November, presenting Omnix Medical to Investors and fellow EIC H2020 champions and raising […]
STUDY: In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii
The rapid worldwide spread of antimicrobial resistance (AMR) underscores the significant need for the development of innovative treatments to fight multidrug-resistant bacteria. Our Scientists at Omnix Medical have published a study demonstrating the potent antimicrobial activity of the novel peptide OMN6 against a wide array of drug-resistant Acinetobacter baumannii. Results point to OMN6 as a novel antimicrobial […]
OMNIX MEDICAL ANNOUNCES THE ADDITION OF TWO NEW PEPTIDE FAMILIES – OMN50 AND OMN70
Omnix Medical is pleased to announce the addition of two new peptide families – OMN50 and OMN70. At Omnix, we are working hard to build our clinical pipeline with new peptide-based drugs that address broad unmet medical needs. Using Omnix drug discovery platform to screen a wide-ranging array of peptides originating from marine organisms, insects […]
OMNIX MEDICAL STARTS PHASE I CLINICAL TRIAL OF NOVEL ANTI-INFECTIVE; FIRST HEALTHY VOLUNTEERS DOSED
New mechanism of action (MoA) addressing global increase of antimicrobial resistance (AMR) burden and shortage of potent anti-infectives JERUSALEM, Israel, April 12, 2022 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced the initiation of a Dutch Phase I clinical trial with its lead compound OMN6. Since […]
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).